TY - JOUR
T1 - Dexamethasone inhalations in RSV bronchiolitis
T2 - A double-blind, placebo-controlled study
AU - Bentur, Lea
AU - Shoseyov, David
AU - Feigenbaum, David
AU - Gorichovsky, Yilena
AU - Bibi, Haim
PY - 2005/7/1
Y1 - 2005/7/1
N2 - Objective: To evaluate the effect of inhaled dexamethasone on hospitalization for respiratory syncytial virus (RSV) bronchiolitis. Study design: A double-blind, placebo-controlled study compared nebulization of dexamethasone versus nebulization of 0.9% saline. Both groups were treated with epinephrine nebulizations. Follow-up continued for 3 mo. Patients and methods: Sixty-one infants with bronchiolitis aged 3 to 12 mo were included. They were randomly allocated to nebulizations with 0.25 mg dexamethasone every 6 h (group 1) or an equivalent amount of normal saline (group 2). Results: No statistically significant differences with respect to clinical score, oxygen saturation, or IV fluid requirement between the groups were noted. Using Kaplan-Meyer's method, the cumulative proportion of in-hospital stay was significantly lower in group 1 compared with group 2, mainly in days 5 and 6 post-hospitalization (p < 0.038). A subgroup of prematurely born children in group 1 had a shorter hospitalization period (6.5 ± 1.7 d) compared with group 2 children (9.1 ± 1.9) (p < 0.018). Follow-up revealed similar wheeze and hospitalization rates in the two groups. Conclusion: Inhaled dexamethasone may reduce the length of hospitalization among infants with acute viral bronchiolitis, especially among those born prematurely.
AB - Objective: To evaluate the effect of inhaled dexamethasone on hospitalization for respiratory syncytial virus (RSV) bronchiolitis. Study design: A double-blind, placebo-controlled study compared nebulization of dexamethasone versus nebulization of 0.9% saline. Both groups were treated with epinephrine nebulizations. Follow-up continued for 3 mo. Patients and methods: Sixty-one infants with bronchiolitis aged 3 to 12 mo were included. They were randomly allocated to nebulizations with 0.25 mg dexamethasone every 6 h (group 1) or an equivalent amount of normal saline (group 2). Results: No statistically significant differences with respect to clinical score, oxygen saturation, or IV fluid requirement between the groups were noted. Using Kaplan-Meyer's method, the cumulative proportion of in-hospital stay was significantly lower in group 1 compared with group 2, mainly in days 5 and 6 post-hospitalization (p < 0.038). A subgroup of prematurely born children in group 1 had a shorter hospitalization period (6.5 ± 1.7 d) compared with group 2 children (9.1 ± 1.9) (p < 0.018). Follow-up revealed similar wheeze and hospitalization rates in the two groups. Conclusion: Inhaled dexamethasone may reduce the length of hospitalization among infants with acute viral bronchiolitis, especially among those born prematurely.
KW - Inhaled dexamethasone
KW - RSV Bronchiolitis
UR - http://www.scopus.com/inward/record.url?scp=22944484101&partnerID=8YFLogxK
U2 - 10.1080/08035250510028407
DO - 10.1080/08035250510028407
M3 - Article
C2 - 16188807
AN - SCOPUS:22944484101
SN - 0803-5253
VL - 94
SP - 866
EP - 871
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
IS - 7
ER -